About This Event
The Inborn Errors of Metabolism team understands that there is still huge value to the inherited metabolic disease community in providing a platform for knowledge sharing and scientific corroboration. As such, the Inborn Errors of Metabolism Drug Development summit has returning to physicality for the 2nd year!
Join colleagues from across the inherited metabolic disease drug developer field and KOLs from industry, academia, and patient advocacy to learn how the major roadblocks to accelerated drug production are being overcome. This summit will serve as a discussion forum to look at where cutting-edge gene therapy modalities interact with existing treatment options, as well as how diseases can be best targeted to treat the huge unmet medical need for rare metabolic diseases.
The potential for biopharma to innovate, actively drive progress and change lives through the provision of treatments of various modalities is growing.
For the first time, the Inborn Errors of Metabolism Drug Development summit will look to examine how the experience within existing pharmacology for rare metabolic diseases can be leveraged with the drug development strategies of those pioneering gene modalities to improve efficacy, safety, and commercial viability.
This is your comprehensive guide to define your drug development path for 2021. Don't miss out on your chance to network with industry leaders and be a part of the only enriched industry forum focused on accelerating the development of better effective treatments for inborn errors of metabolism.